New findings from VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM), published in ...

Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all ...

A recent study published in The New England Journal of Medicine found that transdermal estradiol (tE2) therapy was ...

FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Syncromune ®, Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, an in situ ...

A 58-year-old man presented with a 1-month history of dysuria. Laboratory test results showed an elevated level of serum prostate-specific antigen (PSA) of 8.3 ng/ml (reference range, 0–4 ng/ml).

FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical company pioneering SYNC-T, an in situ personalized combination ...

India, April 2 -- Men with early-stage metastatic prostate cancer may soon be able to postpone the debilitating side effects ...

Final results for the key secondary endpoint of overall survival (OS) from the PEACE-3 trial will be presented by the European Organization for Research and Treatment of Cancer (EORTC) coalition as an ...

Prostate cancer affects many American men. Misinformation can delay diagnosis and treatment. Regular screening is important, especially after age 50. Early stages often show no symptoms. Risk ...